End-of-day quote
Nyse
18:00:00 2024-05-23 EDT
|
5-day change
|
1st Jan Change
|
41.99
USD
|
-0.17%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,714
|
-
|
-
|
Enterprise Value (EV)
1 |
8,241
|
8,089
|
7,905
|
P/E ratio
|
27.5
x
|
26.3
x
|
24.7
x
|
Yield
|
1.29%
|
1.37%
|
1.45%
|
Capitalization / Revenue
|
2.75
x
|
2.61
x
|
2.47
x
|
EV / Revenue
|
2.94
x
|
2.74
x
|
2.53
x
|
EV / EBITDA
|
13.1
x
|
11.6
x
|
10.4
x
|
EV / FCF
|
34.2
x
|
28.3
x
|
23.2
x
|
FCF Yield
|
2.93%
|
3.53%
|
4.3%
|
Price to Book
|
9.4
x
|
7.61
x
|
6.29
x
|
Nbr of stocks (in thousands)
|
200,004
|
-
|
-
|
Reference price
2 |
38.57
|
38.57
|
38.57
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,678
|
2,808
|
2,956
|
3,124
|
EBITDA
1 |
-
|
630.4
|
697.3
|
759.9
|
EBIT
1 |
-
|
443.5
|
477.6
|
506.4
|
Operating Margin
|
-
|
15.8%
|
16.16%
|
16.21%
|
Earnings before Tax (EBT)
1 |
-
|
388
|
424.4
|
453.8
|
Net income
1 |
260
|
285
|
294.4
|
313
|
Net margin
|
9.71%
|
10.15%
|
9.96%
|
10.02%
|
EPS
2 |
-
|
1.400
|
1.465
|
1.559
|
Free Cash Flow
1 |
-
|
241.3
|
285.4
|
340.2
|
FCF margin
|
-
|
8.59%
|
9.65%
|
10.89%
|
FCF Conversion (EBITDA)
|
-
|
38.28%
|
40.93%
|
44.77%
|
FCF Conversion (Net income)
|
-
|
84.67%
|
96.93%
|
108.68%
|
Dividend per Share
2 |
-
|
0.4992
|
0.5283
|
0.5581
|
Announcement Date
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
670
|
720.8
|
704.2
|
711.6
|
697.9
|
760.1
|
EBITDA
1 |
131
|
172.7
|
159
|
164.7
|
144.5
|
193.4
|
EBIT
1 |
90
|
124.7
|
110.7
|
114.5
|
93.56
|
137
|
Operating Margin
|
13.43%
|
17.3%
|
15.72%
|
16.09%
|
13.41%
|
18.03%
|
Earnings before Tax (EBT)
1 |
73
|
111.4
|
96.88
|
105
|
79.23
|
126
|
Net income
1 |
56
|
81.9
|
72.54
|
77.72
|
54.45
|
89.26
|
Net margin
|
8.36%
|
11.36%
|
10.3%
|
10.92%
|
7.8%
|
11.74%
|
EPS
2 |
0.2800
|
0.3854
|
0.3583
|
0.3755
|
0.2749
|
0.4388
|
Dividend per Share
2 |
0.1300
|
0.1275
|
0.1275
|
0.1275
|
0.1275
|
0.1275
|
Announcement Date
|
24-05-20
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
527
|
375
|
191
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.8357
x
|
0.5378
x
|
0.2517
x
|
Free Cash Flow
1 |
-
|
241
|
285
|
340
|
ROE (net income / shareholders' equity)
|
-
|
38%
|
33%
|
29.6%
|
ROA (Net income/ Total Assets)
|
-
|
10.2%
|
10.2%
|
10.6%
|
Assets
1 |
-
|
2,805
|
2,889
|
2,954
|
Book Value Per Share
2 |
-
|
4.100
|
5.070
|
6.130
|
Cash Flow per Share
2 |
-
|
2.180
|
2.730
|
-
|
Capex
1 |
-
|
234
|
243
|
246
|
Capex / Sales
|
-
|
8.32%
|
8.21%
|
7.86%
|
Announcement Date
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
38.57
USD Average target price
41.53
USD Spread / Average Target +7.67% Consensus |
1st Jan change
|
Capi.
|
---|
| -.--% | 7.97B | | +15.80% | 17.48B | | -19.65% | 2.64B | | -12.60% | 2.54B | | -26.54% | 1.81B | | -10.33% | 1.05B | | -8.09% | 1.05B | | +6.12% | 860M | | -18.81% | 763M | | +1.24% | 761M |
Testing Laboratories
|